The localization of specific brainstem lesions may also have diagnostic value in distinguishing MS from clinically similar entities like myelin oligodendrocyte glycoprotein (MOG)-associated disease or neuromyelitis optica spectrum disorder (NMOSD). This evidence concerns the gene OMG and myeloid sarcoma.